NCT05273138Recruiting
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune system, and in particular B lymphocytes, plays a central role in the pathophysiology of SSc. The interactions between B lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated The main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with SSc
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 14 Feb 2022
- Start date
- 8 Jun 2022
- Primary completion date
- Jun 2026
- Lead sponsor
- University Hospital, Lille
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT05273138
What you commit to
- Study type: Observational
- Planned participants: 40
- From 8 Jun 2022 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Dosage of current corticosteroid therapy ≥10mg/d
Other illness
- Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria
Other
- Immunosuppressive treatment within 12 months
- Protected minors or adults
- Pregnant or breastfeeding women
- Deprived of their liberty
- Persons in emergency situations
- Persons who have refused or are unable to give informed consent
Who the study is looking for
- Man or woman over 18 years of age
- With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent
- Being insured
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hop Claude Huriez Chu Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.